Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.66 |
| ▸ | STAT3 | P40763 | 5/20 | 0.66 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362368 | 1.00 | CRBN (0.66) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL29658250 | 0.99 | STAT3 (0.67) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL19475751 | 0.99 | STAT3 (0.67) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL19453139 | 0.99 | STAT3 (0.67) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL19508771 | 0.99 | STAT3 (0.67) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL30312821 | 0.99 | STAT3 (0.67) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL20305742 | 0.99 | STAT3 (0.67) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL29658244 | 0.99 | STAT3 (0.67) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL26813160 | 0.98 | STAT3 (0.64) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL26813299 | 0.97 | STAT3 (0.65) | CRBNDDB1STAT3CA2DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748840-A1 | IMIDAZO[1,2-A]PYRIDINE TYPE IRAK DEGRADATION AGENT AND USE THEREOF | TAINUORUI (TIANJIN) BIOTECHNOLOGY CO., LTD (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | UNIV ANTWERPEN (BE) | 2025-11-20 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12325725-B2 | Cyclin-dependent kinase degraders and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-3752517-B1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BIOVENTURES, LLC | 2020-10-22 | — | — | US | disclosed |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2020041406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019160890-A1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
| WO-2017184995-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20160143902-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885STAT3 145/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885STAT3 145/4885 |
| US-12325725-B2 | Cyclin-dependent kinase degraders and methods of use | CDK9, CDK19, CDK8 | CRBN 597/4885DDB1 359/4885STAT3 1628/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885STAT3 145/4885 |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BCL2, BAX, BCL2L1 | CRBN 520/4885DDB1 134/4885STAT3 932/4885 |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BCL2, BAX, BCL2L1 | CRBN 520/4885DDB1 134/4885STAT3 932/4885 |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | DPP9, DPP7, DPP3 | CRBN 1251/4885DDB1 168/4885STAT3 2861/4885 |
| US-20160143902-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, DBH, SLC6A2 | CRBN 2319/4885DDB1 888/4885STAT3 4571/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885STAT3 145/4885 |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | CRBN 520/4885DDB1 134/4885STAT3 932/4885 |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | TP53, MCL1, LIMS1 | CRBN 1187/4885DDB1 55/4885STAT3 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.